Search

HemAffairs

HemAffairs holds your monthly dose of policy, regulatory and pharma news with impact on hematology in Europe. We also keep you abreast of relevant publications and events to keep an eye on. Enjoy the read! 

 

Read more

Registration & accommodation

Registration is now closed

Individual registrationHybrid registration includes:

In-person access to the scientific and educational sessions of the meeting
Access to the virtual platform
Meeting materials
Coffee/tea breaks on February 9-11, 2023 and lunches on February 10 & 11
Access to the Welcome Reception
Access to the…

Read more

Faculty Information

We are honored that you have agreed to be part of the faculty for the EHA-SfPM Precision Medicine Meeting, to be held on September 25-27, 2024 in Copenhagen, Denmark

On this page, you will find the important deadlines as well as…

Read more

Highlights from the SWG

The SWG:

Was involved with the European Medicines Agency (EMA) on shortages—as part of our policy and regulatory work
Participated in the EMA Healthcare Professionals Policy Officers' Group (HCP POG) review of the ‘Frailty and Older People: Considerations in Medicine Development and…

Read more

Faculty information

We are honored that you have agreed to be part of the faculty for the Highlights of Past EHA (HOPE) MENA 2023, to be held on November 4, 2023 in Antalya, Türkiye.

Read more

Faculty information

We are honored that you have agreed to be part of the faculty for the Highlights of Past EHA (HOPE) Latin America (LA) 2023, to be held on October 26, 2023 in São Paulo, Brazil.

Read more

Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.

 

Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.

Read more

EHA-PTHiT Mini Hematology Tutorial

EHA and the Polish Society of Hematology and Transfusion (PTHiT) are happy to present the second virtual 'mini Tutorial'. This two-day meeting aims to assess and increase your knowledge of the treatment of myeloid and lymphoid diseases.

Read more